MARKET

ENGNW

ENGNW

enGene Therapeutics Inc
NASDAQ
0.1799
-0.0301
-14.33%
Closed 12:04 11/18 EST
OPEN
0.1799
PREV CLOSE
0.2100
HIGH
0.1799
LOW
0.1799
VOLUME
5.00K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
0.1113
MARKET CAP
--
P/E (TTM)
-0.0865
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENGN last week (1109-1113)?
Weekly Report · 2d ago
enGene: Downgrading To 'Sell' On Non-Competitive Efficacy Detalimogene For NMIBC
Seeking Alpha · 5d ago
Leerink Partners Upgrades enGene Therapeutics to Outperform from Market Perform
NASDAQ · 5d ago
Leerink upgrades enGene to Outperform as worst-case scenario off the table
TipRanks · 5d ago
enGene Holdings (ENGN) Receives a Hold from Guggenheim
TipRanks · 5d ago
enGene Therapeutics Price Target Announced at $5.00/Share by Leerink Partners
Dow Jones · 5d ago
enGene Therapeutics Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 5d ago
Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target
Benzinga · 5d ago
More
About ENGNW
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGNW stock methods without spending real money on the virtual paper trading platform.